8

Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

 

Page 2: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

       

Page 3: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

 

Page 4: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

 

Page 5: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

     

Page 6: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

 

   

Page 7: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate

 

Page 8: Newsletter Issue 1 July 2016 - lsrnw.ac.uk · 7/1/2016  · VEGF therapy for triple-negative breast cancer therapy. Prof Doak, Design and evaluation of an antibody-drug conjugate